###### Strengths and limitations of this study

This will be the first PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses)-compliant systematic review to assess the effectiveness and safety of total glucosides of paeony for patients with rheumatoid arthritis. It will provide a high-quality synthesis of current evidence for patients and rheumatologists seeking alternative and beneficial treatments for rheumatoid arthritis.In addition to measuring the methodological quality of included studies using the Cochrane risk of bias tool, this systematic review will evaluate the strength of evidence according to the GRADE approach, to inform clinical decision-makers.Some unpublished randomised controlled trials with negative findings might be missed, so funnel plots will be conducted to detect possible publication bias in order to obtain an objective conclusion.

Introduction {#s1}
============

Description of the condition {#s1a}
----------------------------

Rheumatoid arthritis (RA) is the most common type of chronic autoimmune arthritis that causes pain, stiffness, joint swelling, deformity and loss of function. Over 1.3 million Americans have been estimated to have RA, with a global prevalence of 0.24%.[@R1] [@R2] Data from the Global Burden of Disease 2010 Study show that disability-adjusted life years for RA increased from 3.3 million in 1990 to 4.8 million in 2010.[@R2] Therefore, RA remains a serious disease imposing a considerable burden on patients, their families and society. In order to relieve pain and avoid irreversible joint destruction and disability, RA requires early and systematic treatment with timely adjustment.

Disease-modifying antirheumatic drugs (DMARDs), with effects of lowering disease activity and retarding joint erosion, remain the first-line treatment for RA, but the most common concern about DMARDs is safety. A clinical trial published in the *Annals of the Rheumatic Diseases* reported that methotrexate and leflunomide are associated with increased incidence of hepatotoxicity.[@R3] Some patients have to stop treatment with DMARDs because of adverse effects. In addition, some patients with RA do not respond to DMARDs. Biological agents, also known as biological DMARDs, have been proven to be effective for RA, especially for patients who fail to respond to DMARDs.[@R4] [@R5] However, the very high cost of biological agents limits their application. Furthermore, exposure to biological agents appears to confer an increased risk of serious infection.[@R6] In such cases, natural products with therapeutic potential have drawn increased attention.[@R7]

Description of the intervention {#s1b}
-------------------------------

Total glucosides of paeony (TGP) is an active compound extracted from the roots of a Chinese herb, *Paeonia lactiflora Pallas*, with paeoniflorin accounting for 90% of its active components.[@R8] In China, TGP has been approved as a disease-modifying oral drug for RA since 1998 by the China Food and Drug Administration and is now widely used to treat RA. Many experimental studies have shown the anti-inflammatory and immunoregulatory actions of TGP. [@R9] For example, a study investigating the effects of TGP on synoviocyte activity in rats with collagen-induced arthritis found that TGP could significantly decrease the production of tumour necrosis factor α and interleukin 1 and inhibit the proliferation of synoviocytes.[@R9] Another study revealed that TGP treatment could significantly increase the number and percentage of Treg cells in lupus CD4+ T cells.[@R10] A review published in 2011 reported that paeoniflorin had immunosuppressive effects in rats with adjuvant arthritis.[@R11] In addition, beneficial effects of TGP have been reported in some clinical trials including randomised controlled trials (RCTs).[@R12] [@R13] A multicentre RCT including 370 patients with RA found that TGP might be effective in improving joint function without severe adverse effects.[@R12] A recent RCT published in English which enrolled 268 patients with active RA suggested that TGP could significantly reduce the incidence of liver damage caused by methotrexate and leflunomide.[@R13]

Why it is important to perform this review {#s1c}
------------------------------------------

TGP is a natural plant extract and is widely used to treat RA in China. Although four systematic reviews on TGP in RA treatment are available,[@R14] all are in Chinese and none are adequate with respect to systematic reviewing according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement.[@R18] Two reviews[@R14] [@R15] included seven studies (published in 2005--2007) and 10 studies (published in 2002--2010), respectively, with different methodological quality. However, no subgroup or sensitivity analysis was performed. A review including nine studies between 2005 and 2009 pooled different outcomes using a fixed-effects model.[@R16] The latest review including 15 studies between 2005 and 2011 evaluated a composite outcome measure designated 'overall effect' as the main outcome measure.[@R17] Owing to these shortcomings, the effect of TGP for RA has not be been adequately assessed. Therefore, a comprehensive, updated and PRISMA-compliant systematic review of RCTs is necessary to evaluate the effect of TGP for RA, to inform both clinical practice and further research.

Objectives {#s2}
==========

The objective of this systematic review is to assess the effectiveness and safety of TGP for patients with RA.

Methods and analysis {#s3}
====================

Study registration {#s3a}
------------------

The original protocol of this systematic review has been documented in PROSPERO (ID=CRD42015026345).[@R19] This is a revised version which will also be uploaded to PROSPERO.[@R19] The systematic review will be conducted according to the revised protocol and reported in accordance with the PRISMA statement.

Eligibility criteria {#s3b}
--------------------

### Types of study {#s3b1}

Only RCTs will be eligible for inclusion irrespective of language or publication status. Quasi-randomised trials will be excluded.

### Types of participant {#s3b2}

Adult participants (18 years and older) of any gender or ethnicity, meeting one recognised diagnostic criterion of RA (the 1987 American College of Rheumatology (ACR) criteria or the 2010 ACR/European League Against Rheumatism (EULAR) criteria) will be included.[@R20] [@R21] Studies without description of diagnostic criteria will not be considered.

### Types of intervention {#s3b3}

Studies assessing TGP with or without co-intervention(s) for patients with RA regardless of dosage will be included. Control interventions should be placebo, no treatment, or DMARDs (traditional or biological). TGP compared with any Chinese patent medicine or herbal formulation will be ineligible. Complex intervention involving TGP but no separate report on outcomes of TGP will be excluded. The duration of therapy should be more than 12 weeks.

### Types of outcome measure {#s3b4}

#### Primary outcomes {#s3b4a}

1.  Disease improvement (measured by any validated improvement criteria of RA, such as the ACR20 response[@R22])

2.  Disease remission (measured by any validated remission criteria of RA, such as the Disease Activity Score in 28 joints less than 2.6[@R23] [@R24])

#### Secondary outcomes {#s3b4b}

1.  Adverse effects

2.  Pain (measured by a visual analogue scale)

3.  Health-related quality of life (measured by a validated tool)

4.  C-reactive protein

5.  Erythrocyte sedimentation rate

Search methods {#s3c}
--------------

### Electronic searches {#s3c1}

The following databases will be searched from their inception to February 2016: PubMed, Embase, Cochrane Central Register of Controlled Trials, Chinese Biomedical Database (CBM), China National Knowledge Infrastructure (CNKI), Wanfang Database and Chinese Scientific Journal Database (VIP).

### Searching other resources {#s3c2}

Clinical trials registry platforms will be searched, including the International Clinical Trials Registry platform (<http://www.who.int/ictrp/network/primary/en/>), the US National Institutes of Health Ongoing Trials Register (<http://clinicaltrials.gov/>), and the ISRCTN registry (<http://www.controlled-trials.com/>). We will also screen the reference lists of retrieved articles to identify missing eligible studies.

### Search strategies {#s3c3}

Search strategies in English electronic databases will be listed in [online supplementary appendix](#SM1){ref-type="supplementary-material"} 1, and will be adapted for other resources with appropriate terms. No language restriction will be applied.

10.1136/bmjopen-2015-010116.supp1

Study selection {#s3d}
---------------

Two reviewers will independently screen all titles and abstracts of the records. Full texts of potentially eligible studies will be retrieved for further identification according to the eligibility criteria. Any uncertainty or discrepancy will be resolved by discussion. Details of the study screening process will be shown as in [figure 1](#BMJOPEN2015010116F1){ref-type="fig"}.

![Flow diagram of study search and identification. RA, rheumatoid arthritis; TGP, total glucosides of paeony.](bmjopen2015010116f01){#BMJOPEN2015010116F1}

Data extraction {#s3e}
---------------

Two reviewers will independently extract data in accordance with a predesigned data form using Excel (version Microsoft Excel 2007). Data will be checked by an additional two reviewers. Disagreements will be resolved by discussion.

Extracted information will comprise the following sections: General information (publication years, number of authors, the first author, study design, sample size, demographics, setting)Participants (diagnostic criteria, condition of RA, baseline comparison, withdrawals, loss to follow-up)Interventions (dosage, administration, duration, follow-up, comparisons)Outcome measures, results and adverse effects

We will seek missing information by contacting the original authors whenever possible. Any discrepancies will be resolved by discussion or consulting a third reviewer.

Quality assessment {#s3f}
------------------

### Assessment of risk of bias {#s3f1}

Two reviewers will independently evaluate the risk of bias for each included study using the Cochrane Collaboration\'s risk of bias tool, consisting of the following items: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias.[@R25] We will judge each item as low, high or unclear risk of bias. Any uncertainty or discrepancy will be resolved by consulting a third reviewer.

### Quality of evidence {#s3f2}

We will judge the quality of evidence for the main comparison according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method.[@R26] The following five factors will be judged for each outcome in the main comparison: limitations in study design and execution, inconsistency of results, indirectness of evidence, imprecision, and publication bias. Accordingly, the quality of the evidence for each outcome will be graded as high, moderate, low or very low.

Data analysis {#s3g}
-------------

RevMan V.5.3 software will be used for data analysis. Studies included will be stratified by different types of comparison. Dichotomous data will be reported as risk ratios, and continuous data as mean difference or weighted mean difference, both with their 95% CIs. We will perform intention-to-treat analysis where possible. We will attempt to obtain missing or incomplete data by contacting the original authors.

Meta-analyses will be performed if the data are sufficiently homogeneous, both statistically and clinically. Otherwise, analyses will be descriptive. Before pooling of data, heterogeneity will be tested using I^2^. If heterogeneity is low (I^2^ ≤50%), a fixed-effects model will be applied to analyse data, and a random-effects model will be used when heterogeneity is moderate (50%\<I^2^\<75%). Data will not be pooled when heterogeneity is high (I^2^≥75%).

We will perform subgroup analyses according to different clinical characteristics (eg, different durations), and sensitivity analyses on the basis of study quality where possible. Funnel plots will be created to detect possible publication bias when sufficient studies (more than eight) are identified.

In addition, we will generate a 'Summary of findings' table using the GRADE profiler (V.3.6) to calculate the relative effect and the number of patients needed to treat in order to present important outcomes and the strength of evidence supporting these outcomes under the main comparison.

Ethics and dissemination {#s3h}
------------------------

Ethics approval is not required, as this study will not involve patients. The results of this study will be submitted to a peer-reviewed journal for publication, to inform both clinical practice and further research.

Discussion {#s4}
==========

RA can cause pain, joint destruction, and disability, placing a considerable burden on patients and society. Currently, DMARDs are the first-line treatment for RA. However, some patients have to stop treatment with DMARDs because of adverse effects, and some patients do not respond to DMARDs. Biological agents have been proven to be effective for RA, but their very high cost limits their use. In China, TGP, a natural plant extract, has been approved as a disease-modifying drug for RA since 1998 and is widely used for RA treatment. Some RCTs have reported beneficial effects of TGP in RA treatment, alone or in combination with other DMARDs. However, the effectiveness and safety of TGP for RA have not been systematically reviewed according to the PRISMA statement. This systematic review will provide a high-quality synthesis of current evidence for patients and rheumatologists seeking alternative and beneficial treatments of RA.

The strengths of this systematic review are twofold. First, this will be the first PRISMA-compliant systematic review to assess the effectiveness and safety of TGP for patients with RA. The study selection, data extraction and quality assessment will be conducted independently by two reviewers. Second, in addition to measuring methodological quality of each included study, this systematic review will evaluate the strength of evidence according to the GRADE approach. However, limitations may also exist. Although we will conduct an extensive and unbiased search, some unpublished RCTs with negative findings might be missed. We will detect possible publication bias through funnel plots in order to obtain an objective conclusion. In addition, it might be difficult to retrieve raw data from some published papers. We will try to contact the original authors to seek information. However, we believe the results of this study could provide objective evidence on the effects of TGP in RA treatment, which will be beneficial for patients and practitioners.
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